Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Betta Pharmaceuticals Partners with Westlake University on Pharma Innovation

Fineline Cube Jan 8, 2026
Company Deals

Viva Biotech and CMS Forge AI-Powered Drug Development Alliance

Fineline Cube Jan 8, 2026
Company Deals

Hisun and ECNU Forge AI Drug Discovery Partnership

Fineline Cube Jan 8, 2026
Company Deals Drug

Sciclon Licenses Augtyro Promotion Rights from Zai Lab for China Market

Fineline Cube Jan 8, 2026
Company Deals Drug

Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal

Fineline Cube Jan 8, 2026
Policy / Regulatory

NMPA Issues Priority Review Guidelines for Clinically Urgent Overseas Drugs

Fineline Cube Jan 8, 2026
Company Deals Drug

Sciclon Licenses Augtyro Promotion Rights from Zai Lab for China Market

Fineline Cube Jan 8, 2026
Company Drug

Hengrui’s Retlirafusp α Wins NMPA Approval for First-Line Gastric Cancer

Fineline Cube Jan 8, 2026
Company Deals

Betta Pharmaceuticals Partners with Westlake University on Pharma Innovation

Fineline Cube Jan 8, 2026

Betta Pharmaceuticals Co., Ltd. (SHE: 300558) and Westlake University announced a strategic partnership to advance...

Company Deals

Viva Biotech and CMS Forge AI-Powered Drug Development Alliance

Fineline Cube Jan 8, 2026

Viva Biotech (HKG: 1873) and China Medical System Holdings Limited (CMS; HKG: 0867, SGX: 8A8)...

Company Deals

Hisun and ECNU Forge AI Drug Discovery Partnership

Fineline Cube Jan 8, 2026

Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA: 600267) and East China Normal University (ECNU) announced a...

Policy / Regulatory

NMPA Issues Priority Review Guidelines for Clinically Urgent Overseas Drugs

Fineline Cube Jan 8, 2026

The National Medical Products Administration (NMPA) issued Announcement No. 3, 2026 on further optimizing the review...

Company Deals Drug

Sciclon Licenses Augtyro Promotion Rights from Zai Lab for China Market

Fineline Cube Jan 8, 2026

Sciclon Pharmaceuticals (HKG: 6600) forged a collaboration with Zai Lab (NASDAQ: ZLAB, HKG: 9688), securing exclusive promotional rights...

Company Drug

Hengrui’s Retlirafusp α Wins NMPA Approval for First-Line Gastric Cancer

Fineline Cube Jan 8, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276, HKG: 1276) announced that its self-developed Category 1 drug,...

Company Deals Drug

Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal

Fineline Cube Jan 8, 2026

Pfizer Inc. (NYSE: PFE) and Cartography Biosciences, Inc. announced a strategic collaboration to discover tumor-selective...

Company Drug

Sanofi’s Redemplo Wins NMPA Approval as First siRNA for Familial Chylomicronemia

Fineline Cube Jan 8, 2026

Sanofi (NASDAQ: SNY) announced that Redemplo (plozasiran sodium injection), the world’s first small interfering RNA...

Company Drug

Bayer’s Cevatertinib Wins Breakthrough Therapy Designation for HER2‑Mutant NSCLC

Fineline Cube Jan 8, 2026

Bayer AG (VIE: BAYN) announced that cevatertinib (BAY 2927088) has been granted Breakthrough Therapy Designation (BTD)...

Company Deals

ImmuneOnco Terminates Axion Licenses, Regains Global Rights to IMM2510 and IMM27M

Fineline Cube Jan 8, 2026

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541) announced it has terminated its License and Collaboration Agreement...

Company Drug

HutchMed’s Sovleplenib Meets Phase 3 Primary Endpoint in wAIHA, Targets NDA Filing

Fineline Cube Jan 8, 2026

HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that the Phase 3 registration part of the...

Company Deals

Structure Therapeutics Licenses GLP-1 Patents to Roche for $100 Million Upfront

Fineline Cube Jan 8, 2026

Structure Therapeutics Inc. (NASDAQ: GPCR) announced that its wholly‑owned subsidiary, Gasherbrum Bio, entered into a...

Company Drug

Sichuan Biokin’s BL-B01D1 ADC Wins Priority Review for ESCC in China

Fineline Cube Jan 8, 2026

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that iza-bren (izalontamab brengitecan, BL-B01D1), its first‑in‑class...

Company Deals

Ikarovec and VectorBuilder Sign $1 Billion AAV Capsid Deal for AMD Gene Therapy

Fineline Cube Jan 8, 2026

Ikarovec, a UK‑based gene therapy company, and VectorBuilder, a leader in gene delivery, announced a...

Company Drug

Zai Lab’s Repotrectinib Wins NMPA sNDA for NTRK Fusion-Positive Solid Tumors

Fineline Cube Jan 8, 2026

Zai Lab Ltd. (NASDAQ: ZLAB, HKG: 9688) announced that the supplemental New Drug Application (sNDA)...

Company Deals

Mabwell Partners with Sentonix on Neurodegenerative Disease Drug Discovery Alliance

Fineline Cube Jan 8, 2026

Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced a global strategic cooperation agreement with Sentonix,...

Company Deals

Amgen Acquires Dark Blue Therapeutics for $840 Million to Expand AML Portfolio

Fineline Cube Jan 8, 2026

Amgen Inc. (NASDAQ: AMGN) announced the acquisition of Dark Blue Therapeutics Ltd., a privately held...

Company Drug

BeOne’s Sonrotoclax Wins Conditional NMPA Approval for BCL-2 Inhibitor in CLL/SLL and MCL

Fineline Cube Jan 8, 2026

BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that its self‑developed Class 1 innovative drug...

Company Drug

XtalPi’s RTX-117 Wins NMPA IND for CMT Therapy

Fineline Cube Jan 8, 2026

ReviR Therapeutics, an incubated company of XtalPi (HKG: 2228), announced that RTX-117 has received Investigational...

Company Drug

Ascentage’s PROTAC BTK Degrader APG-3288 Wins FDA IND for B-Cell Malignancies

Fineline Cube Jan 8, 2026

Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced that the U.S. Food and Drug Administration (FDA)...

Posts pagination

1 2 … 606

Recent updates

  • Betta Pharmaceuticals Partners with Westlake University on Pharma Innovation
  • Viva Biotech and CMS Forge AI-Powered Drug Development Alliance
  • Hisun and ECNU Forge AI Drug Discovery Partnership
  • NMPA Issues Priority Review Guidelines for Clinically Urgent Overseas Drugs
  • Sciclon Licenses Augtyro Promotion Rights from Zai Lab for China Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Betta Pharmaceuticals Partners with Westlake University on Pharma Innovation

Company Deals

Viva Biotech and CMS Forge AI-Powered Drug Development Alliance

Company Deals

Hisun and ECNU Forge AI Drug Discovery Partnership

Policy / Regulatory

NMPA Issues Priority Review Guidelines for Clinically Urgent Overseas Drugs

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.